Table 3.
The clinical trials of IDH inhibitors
| NCT number | Conditions | Interventions | Phase | Number enrolled |
|---|---|---|---|---|
| NCT04176393 | R/R AML | Ivosidenib | Phase 1 | 30 |
| NCT03564821 | IDH1-mutated myeloid neoplasms | Ivosidenib | Phase 1 | 18 |
| NCT03245424 | AML | Ivosidenib | NA | NA |
| NCT02074839 | R/R AML/MDS/other IDH1-mutated positive hematologic malignancies | Ivosidenib | Phase 1 | 291 |
| NCT03839771 | AML/MDS | Ivosidenib | Phase 3 | 968 |
| NCT03503409 | AML/MDS | Ivosidenib | Phase 2 | 68 |
| NCT05282459 | AML | Enasidenib | Phase 1/2 | 48 |
| NCT04203316 | R/R AML | Enasidenib | Phase 2 | 10 |
| NCT03515512 | AML/CML | Enasidenib | Phase 1 | 23 |
| NCT01915498 | Hematologic neoplasms | Enasidenib | Phase 1 | 345 |
| NCT03720366 | AML | Enasidenib | Phase 1 | 40 |
| NCT03728335 | AML | Enasidenib | Phase 1 | 15 |
| NCT03881735 | R/R AML | Enasidenib | Phase 2 | 0 |
| NCT03744390 | AML/MDS | Enasidenib | Phase 2 | 68 |
| NCT03723057 | AML | Enasidenib | NA | NA |
| NCT04522895 | AML/MDS/CML | Enasidenib | Phase 2 | 50 |
AML acute myeloid leukemia, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, NA not applicable, R/R relapsed/refractory